Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 5:52 PM ET

Life Sciences Tools and Services

Company Overview of Warnex Inc.

Company Overview

Warnex Inc. does not have significant operations. Prior to December 10, 2012, the company provided analytical and bioanalytical services. Warnex Inc. is headquartered in Dorval, Canada. As of July 8, 2014, Warnex Inc. operates as a subsidiary of Diagnos Inc.

1375 TransCanada Highway

Suite 200

Dorval, QC H9P 2W8






Key Executives for Warnex Inc.

Interim Chief Executive Officer, Interim Chief Financial Officer, Director, Member of Audit Committee, Member of Corporate Governance Committee and Member of Human Resources & Remuneration Committee
Vice President of Legal Affairs and Corporate Secretary
Compensation as of Fiscal Year 2015.

Warnex Inc. Key Developments

Warnex Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014

Warnex Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2014. For the quarter, the company reported net and comprehensive loss of CAD 99,402 compared to net and comprehensive loss of CAD 453,637, or CAD 0.02 per basic and diluted share for the same quarter in 2012. Net cash from operations was CAD 168,369 compared to net cash used in operations of CAD 168,369 last year. Revenues were CAD 99,402 against CAD 453,637 a year ago.

Warnex Inc., Annual General Meeting, Jun 26, 2014

Warnex Inc., Annual General Meeting, Jun 26, 2014. Agenda: To vote on the amalgamation agreement.

Warnex Inc. Announces Consolidated Earnings Results for the Full Year Ended Dec. 2013

Warnex Inc. announced consolidated earnings results for the full year ended Dec. 2013. For the year the company reported revenues of $1,037,943 against $4,764,646 for the previous year. Net loss and comprehensive income of $1,962,943 or $0.07 per diluted per share against net earnings and comprehensive income of $1,023,178 or $0.04 per diluted per share for the previous year. Net cash used in operations was $623,815 against $2,883,383 for the previous year.

Similar Private Companies By Industry

Company Name Region
Nova Molecular Inc. Americas
PharmaNet Canada, Inc. Americas
Innovascreen, Inc. Americas
NAEJA Pharmaceutical Inc. Americas
Robarts Research Institute Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Warnex Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at